The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
The Oncology Care Model (OCM) was a great program that led to practice transformation and improved patient care, but there needs to be a way to address the high cost of cancer therapies, said Marcus Neubauer, MD, chief medical officer of the US Oncology Network.
Transcript
What are you hoping comes after the Oncology Care Model (OCM)? What learnings from OCM should be in the successor model?
Yeah, I think that, first of all, it remains to be seen if there will be a successor, I hope there will be. I think that the OCM has been very good for patients. I think it's been good for changing the way that oncology is delivered. One of the things about the OCM, that's not talked about as much as cost savings and bending the cost curve is the change in the way care is delivered. And it really drove a lot of good things. I think patients were getting more attention, more coordination of care, more efforts to keep people out of the hospital and the emergency room, better evaluation of data to learn from the program. So, there was a lot of good with the OCM, I thought it was actually a great program and did a lot of good things for practices and, again, for patients.
But it's over, you know, in about 6 months. So, I think that it would be great if Medicare, [Center for Medicare and Medicaid Innovation] looked at another model—one that continues to drive value—and also look at ways to reimburse [and] pay for cancer care in an appropriate way. It's very, very expensive. There is a lot of utilization that’s not always needed. And I think there's still value in trying to explore better ways to pay for what's very expensive care.
Was there something missing from OCM that you would like to see in the successor model?
I think that in a subsequent model, I would continue to support the more comprehensive staff and infrastructure at practices. That is expensive; it's typically not reimbursed. So, to find a way to support that I think would be very important. Otherwise, there's a risk that nutritionist and social workers and community practice really can't be afforded. So, I think that's one thing I would definitely try to keep going in the next model, if you will.
I think that there does need to be continued focus on drugs. When you look at the baseline data for the OCM. The data that was calculated prior to the program beginning—2012 to 2015—drugs took up about 40% of the overall cost per episode. They're now at about 70%. This isn't necessarily a bad thing. There's been a lot of advances in drug therapy, but it's very, very, very expensive and that will be the focus whether you know participants like it or not.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More